JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.

Front Psychiatry May 12, 2023 DOI: 10.3389/fpsyt.2023.1191970 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Editorial Peer reviewed
Key points	Argues that the use of cannabinoid and psychedelic medicines for psychiatric disorders requires further rigorous research to assess their appropriateness and safety.

Abstract

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.